www.hivandhepatitis.com

Back HCV Treatment

Merck Discontinues Development of Experimental Hepatitis C Drugs

Details
Category: Experimental HCV Drugs
Published on Thursday, 12 October 2017 00:00
Written by HIVandHepatitis.com
  • Print

Late last month Merck announced that it was halting further development of 2 investigational hepatitis C therapies. The first is a 3-drug coformulation containing the HCV protease inhibitor grazoprevir, the NS5A inhibitor ruzasvir, and the HCV polymerase inhibitor uprifosbuvir. The second is a 2-drug combo containing ruzasvir and uprifosbuvir.

alt

Read more:

Subcategories

Copyright © 2023 www.hivandhepatitis.com. All Rights Reserved. Designed by JoomlArt.com. Joomla! is Free Software released under the GNU General Public License.

Bread and Roses Web DesignWeb Design and Development by Bread and Roses Web Design